Aspen Pharmacare H1 2025: strong growth despite currency & tax challenges
Aspen H1 2025: EBITDA up 12%. Pharma thrives, Mounjaro launches, Manufacturing doubles profits. GLP-1 focus for future.
Aspen Pharmacare's First Half 2025 Performance in Brief
Aspen Pharmacare's first half 2025 results demonstrate a company effectively balancing growth and challenges, with a 4% revenue increase (9% in constant currency) and an impressive 12% EBITDA growth showcasing strong operational efficiency. The pharmaceuticals division thrived with prescription brands growing 19%, bolstered by the successful Mounjaro launch in South Africa and strategic Latin American acquisitions, while the manufacturing division transformed into a key profit center with doubled earnings from sterile production capabilities. Despite headwinds from currency fluctuations, increased tax burdens from new OECD regulations, and temporary declines in API segments, Aspen maintains strategic momentum through its focused expansion in high-growth therapeutic areas, particularly GLP-1 products for diabetes and obesity treatment, alongside its valuable Novo insulin manufacturing contract, positioning the company for sustained future growth in these rapidly expanding markets.
Segment Analysis
The results show balanced growth across its business units:
Pharmaceuticals
The strong 19% growth in prescription brands is particularly notable, as these typically carry higher margins than generic products.
The successful Mounjaro launch in South Africa demonstrates Aspen's ability to commercialize new therapies in emerging markets. The Latin American acquisitions show strategic geographic expansion.
Manufacturing
The doubling of profits in this division signals a significant transformation in Aspen's business model. The strength in sterile manufacturing suggests Aspen is capitalizing on global pharmaceutical outsourcing trends and establishing itself as a key contract manufacturing player.
Challenges and Risks
Aspen Pharmacare faces several notable headwinds despite its overall strong performance. Currency fluctuations, particularly the strength of the South African Rand, have diluted the company's reported growth figures, creating a gap between operational and reported performance. The implementation of the OECD's global minimum tax rate (BEPS Pillar 2) in South Africa has increased Aspen's effective tax burden, putting additional pressure on net earnings. Additionally, the company needs to address the temporary declines in its API and Heparin segments to ensure these don't become longer-term weaknesses. These challenges require continued strategic management attention to prevent them from undermining the positive momentum in other business areas.
Future Outlook
Aspen's focus on GLP-1 products is particularly strategic given the explosive growth in this therapeutic area for diabetes and obesity treatment. This could be a significant growth driver if executed well. The Novo insulin contract also positions Aspen in the diabetes care space, which continues to see global demand growth.
Long term broker ratings and price target
This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only
